IMPORTANT ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit Against Clovis Oncology, Inc. & Strongly Encourage...
November 23 2015 - 7:47PM
Business Wire
Goldberg Law PC (www.Goldberglawpc.com) announces that a class
action lawsuit has been filed against Clovis Oncology, Inc.
(“Clovis” or the “Company”) (NASDAQ: CLVS). Investors who purchased
or otherwise acquired shares between October 31, 2013 and November
13, 2015, inclusive (the “Class Period”), are encouraged to contact
the Firm in advance of the January 19, 2016, lead plaintiff motion
deadline.
If you are a shareholder who suffered a loss during the Class
Period, we advise you to contact Michael Goldberg or Brian Schall,
of Goldberg Law PC, 13650 Marina Pointe Dr. Suite 1404, Marina Del
Rey, CA 90292, at 800-977-7401, to discuss your rights without cost
to you. You can also reach us through the firm’s website at
http://www.Goldberglawpc.com, or by email at
info@goldberglawpc.com.
The class in this case has not yet been certified, and until
certification occurs, you are not represented by an attorney. If
you choose to take no action, you can remain an absent class
member.
According to the complaint, the Company made misleading
statements to investors and/or failed to disclose that: (a) the New
Drug Application (“NDA”) that Clovis submitted to the FDA for
rociletinib contained immature data sets; (b) Clovis’ Breakthrough
Therapy designation submission contained immature data set based
primarily on unconfirmed responses; (c) Clovis presented interim
data publicly and at medical meetings that included a data set
based primarily on unconfirmed responses; (d) as the efficacy data
matured, the number of patients with an unconfirmed response who
converted to a confirmed response was lower than expected; (e) as a
result of the foregoing, Clovis’ NDA was likely to be delayed
and/or rejected by the FDA; and (f) Clovis was in possession of
data during its third-quarter conference call held on November 5,
2015, which demonstrated that the confirmed rociletinib response
rate is lower than what was previously disclosed.
If you have any questions concerning your legal rights in this
case, please immediately contact Goldberg Law PC at 800-977-7401,
via email at info@goldberglawpc.com, or visit our website at
Goldberglawpc.com.
Goldberg Law PC represents shareholders around the world and
specializes in securities class actions and shareholder rights
litigation.
This press release may be considered Attorney Advertising in
some jurisdictions under the applicable law and ethical rules.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151123006385/en/
Goldberg Law PC, Los AngelesMichael Goldberg, Esq.
800-977-7401Brian Schall, Esq.
800-977-7401info@goldberglawpc.comGoldberglawpc.com
Clovis Oncology (NASDAQ:CLVS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Clovis Oncology (NASDAQ:CLVS)
Historical Stock Chart
From Sep 2023 to Sep 2024